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Recent publication of the American Academy of Neurology SUDEP guidance high-
lighted the importance to American clinicians of making people with epilepsy aware of 
SUDEP risk. It is the first guideline to do this in the United States. It follows precedent 
set out in the UK by National Institute of Clinical Excellence in 2004. While a significant 
achievement, the lack of clarity of how to deliver this guidance in an enduring and 
person-centered manner, raises concerns on how its long-term effectiveness in risk 
mitigation. Shared decision-making with an emphasis on delivering person-centered 
communication to foster self-management strategies is increasingly recognized as the 
ideal model of patient–clinician communication in chronic diseases such as epilepsy. 
The tension between delivering evidence-based risk information, yet, tailoring it to the 
individual is complex. It needs to incorporate the potential for change not only in seizure 
factors but also other health and social factors. Safety advice needs to be dynamic 
and situation sensitive as opposed to a “one off” discussion. As a significant minority 
of people with epilepsy have drug-resistant seizures, the importance of keeping the 
advice contextual at different intervals of the person’s life cannot be overstated as 
many of them are managed in primary care. We present some exploratory work, which 
identifies the need to improve communication at a primary care level and to review risks 
regularly. Regular reviews using a structured risk factor checklist as a screening tool 
could identify, sooner, people who’s health issues are worsening and justify referrals to 
specialists.
Keywords: risk factors, communication, classify, risk assessment, sUDeP
Living is a risky business. Risk is the chance that an activity or action could lead to harm. 
Currently, there is no such option as zero risk. People will generally modify behavior and change 
lifestyle if they feel that there is a person-centered advantage or benefit. To bring about such a 
change, people need to know and comprehensively understand specific risks. Health risks are 
conveyed to individuals by clinicians in a myriad of ways of variable quality and effectiveness. 
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As there are no specific “rules,” a host of clinician and individual 
factors play a role in person-centered communication (1). The 
lack of a clear structure to capture systemically this quality of 
communication could influence outcomes. The current level 
of evidence and the availability of a structure to deliver the 
information needed for individuals to be able to understand 
and be more aware of their distinct risk underpin the strength 
of individual risk avoidance.
New guidance from The American Academy of Neurology 
(AAN) recognizes the importance of communicating the risk of 
Sudden Unexpected Death in Epilepsy (SUDEP) to people with 
epilepsy (2). It is a welcome document, the first of its kind for 
American clinicians, which was critically developed and which 
provides clarity on the current level of evidence of the various 
risk factors highlighted to date in the literature. It also establishes 
the importance of a discussion of these risks with individuals 
mirroring the position taken by the UK’s National Institute of 
Clinical Excellence (NICE) (3) guidance for epilepsy since 2004. 
While this is a major step forward, similar to NICE, the AAN 
guidance lacks elaboration on how to deliver person-centered 
risk assessment. It stops short of providing guidance or support 
to empower clinicians in having this critical conversation in 
clinic. Another concern with such guidance is that the discus-
sion of SUDEP risk is expected to occur once at the time or near 
the time of diagnosis. There seems to be a lack of recognition of 
the importance to keep updating risk assessment and feedback 
based on the course an individual’s epilepsy takes and how this 
may change. It has been shown in chronic conditions, epilepsy 
in particular that risk can change over time and is heavily influ-
enced by varying life factors (4). People with epilepsy, often to 
their detriment, are rarely aware of changing risk. Thus, what 
can start as “low” risk can over time switch to a “higher” risk 
without the individual or the care giver or even the clinician 
being fully aware.
It is important that risk assessments in epilepsy are person-
centered, contextual, and focused on the “here and now,” and 
reviewed at regular intervals to ensure that there is a full picture 
of individual risk status. It is worth noting that most people with 
epilepsy, especially in countries where there are public health 
systems, as in the UK, are not usually supported by specialist 
epilepsy services but mainly by primary care where knowledge of 
up-to-date epilepsy and associated risk issues may be lacking and 
vary significantly. This can also be case when neurologists who 
are not epilepsy specialists (5) are involved.
The extent of the problem is highlighted by the fact that in 2013 
in the UK around 1,200 people died due to epilepsy, which was 
roughly the same number who died from asthma in the same year 
(6). This is despite the number of people with asthma being 10 
times larger (6). The data from National Statistics suggested that 
up to 60% of the epilepsy deaths could have been avoidable while 
only a quarter of asthma deaths were identified as preventible 
(6). This suggests that there is significant room for improvement 
in the way risk identification and management of people with 
epilepsy happen in the community.
In primary care (the General Practice system), epilepsy 
remains a common and regular presentation with Public Health 
expenditure in the UK for neurological conditions, second only 
to stroke (7, 8). Around 600 people with epilepsy in the UK 
die of SUDEP each year (7, 9). It is likely that these statistics 
underrepresent the true number of epilepsy deaths each year 
in the UK.
In 2004, an incentivizing scheme for the provision of quality 
care and to standardize improvement in the delivery of pri-
mary care was introduced in England called Quality Outcome 
Framework (QOF). The focus was to encourage primary care 
to manage common chronic conditions and enable the imple-
mentation of preventative strategies (10). Epilepsy had four QOF 
outcome indicators, one of which included an annual monitoring 
of people aged 18 and over on drug treatment. Epilepsy drug 
treatment monitoring was withdrawn from the scheme in 2014, 
raising concerns as there are now less opportunities to review 
individual risk changes as a result of the abandonment of the 
annual reviews. No clear evidence has, however, emerged as yet 
to the impact of this (11).
The SUDEP and Seizure Safety Checklist (“Checklist”)1 is 
a free, practical, evidence-based tool available in the UK for 
regular clinical use (12, 13). Its aim is to help person-centered 
communication to empower individuals and families with 
epilepsy to take shared responsibility with clinicians to make 
meaningful changes to improve their seizure risk outcomes. 
It also enables clinicians to identify change and compare with 
baseline in a structured manner. Description of the Checklist is 
provided in Appendix 1.
The Checklist has 19 modifiable and non-modifiable fac-
tors, providing an outline for clinician’s discussions with 
individuals, which can be repeated annually or when a person 
with unstable epilepsy is reviewed urgently or routinely. 
Clinicians in secondary care have found the tool practical and 
time efficient (10 min), but it has not yet been systematically 
used in primary care though anecdotal feedback is that it is 
used significantly by clinicians working in primary care or out 
in the community.
The concept has been tested as a telehealth project for a year 
in a single site large primary care practice in mid-Cornwall 
having 16,000 people registered to it to risk assess “high risk” 
individuals with epilepsy in the catchment (14). “High risk” 
was defined as over 10 years of treatment-resistant seizures but 
“stable” in the community. The telehealth team called on a three 
monthly basis and ran the Checklist with the registered users. 
All results were communicated back to the GP. Of the 46 people 
with epilepsy in the practice who received the telehealth screen-
ing, 17 were referred for several interventions during the year 
that would not have happened without the on-going screening. 
However, a problem of this study was that it identified “high 
risk” based on a single factor of 10 years treatment resistance 
and not on a holistic risk issue. Thus, another study was set up to 
look at all registered people with epilepsy in a different primary 
care practice.
The setting was a medium sized primary care facility cover-
ing a mixed urban and large rural area in SW England covering 
around 12,000 people. A database identifying all people with 
1 https://www.sudep.org/checklist (Accessed: October 28, 2017).
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epilepsy in the practice with a baseline risk score was proposed 
using the Checklist factors. The purpose was to allow for rapid re-
valuation of risk status during an annual review or consultation 
to help identify seizure risk change using the Checklist to help 
recognize, categorize, and stratify seizure risk. Person-centered 
advice could then be provided based on the changed findings. 
Using the facilities, standard digital clinical management system, 
EMIS Web (EmisHealth, Leeds, UK), a search was created to 
identify anyone with epilepsy, epileptiform conditions, or sei-
zures. Each risk factor of the Checklist was then identified and 
relating codes were then automatically searched in the database. 
This was done for each individual, thus allowing individual risk 
score analysis as well as analysis of the population.
A total of 107 target individuals were identified. All 19 risk 
factors were applied. The mean score was 4.1. The range was from 
1 to 9 though only two people scored 9 and three had scores 
of 8. There were no data coded or any documented evidence 
for four of the risk factors (nocturnal surveillance, pregnancy, 
prone sleeping position, and nocturnal seizure presence) in any 
individual.
Undertaking this evaluation resulted in each of the individu-
als at the primary care facility undergoing a baseline screen and 
s risk factors scoring. It has also identified common risk factors 
and individual modifiable factors. The perceived lack of aware-
ness for risk among primary care clinicians and the lack of 
clinical codes to identify the presence of major established risk 
factors is of concern. Given the overall high standards followed 
in this facility, it could be expected that similar shortcomings 
would be seen in other practices leading to concerns of the gap 
in knowledge and awareness.
These data were presented to the facility clinical practition-
ers (physicians and nurses) and the realization that some risk 
factors may have been missed in certain individuals’ stimulated 
discussion. This was highlighted by the discussion around the 
risk factor of nocturnal seizures where no coding data were 
present. Facility practitioners acknowledged that it was not a 
practice to ask of nocturnal events during reviews. As this is 
a modifiable high risk factor, this warrants full incorporation 
into records as it may help reduce risk in certain patient-groups. 
Indeed, as a result of these findings, the annual epilepsy review 
structure of the facility was changed to include the Checklist 
risk factors.
The strength of the Checklist was its ability to motivate risk 
considerations of SUDEP with people with epilepsy and their 
families. All 107 identified when reviewed and given feedback 
felt the conversation was useful again confirming the impor-
tance of person-centered discussion of risk. It showcased the 
importance of sharing risk knowledge in giving ownership to 
people with epilepsy and their carers. This supports findings of 
another recent study where the structured use of the Checklist in 
specialist epilepsy clinics led to the reduction of risk scores. It has 
helped possibly reduce the burden of SUDEP in the long term. 
It should be stressed that for most risk factors, it is not clear if a 
modification of these factors changes the actual SUDEP risk and 
this is an area which needs further exploring (2).
This exercise has also allowed positive discussions and learn-
ing among physicians, nurses, and individuals within the facility 
about SUDEP and risk factors and has acted as a catalyst to 
hopefully improve care, monitoring and outcomes in the longer 
term. It also highlights the value of risk identification and cod-
ing in epilepsy community care, through the use of the clinical 
Checklist. The value of education and empowerment is intuitive 
in all areas of clinical risk reduction and is particularly relevant 
in epilepsy.
This intervention was well received and is easily translatable 
to most primary care settings, so the following recommendations 
would be reasonable:
 1. People with epilepsy should have an annual seizure safety risk 
assessment at primary care.
 2. An earlier interim assessment needs to be triggered if any 
person with epilepsy presents with: decline in seizure control, 
alteration to AEDs or relevant medications, change in comor-
bidities in particular use of alcohol or other substances or with 
psychiatric issues.
It is appreciated that the postulated move to stratify risk 
with the current level of evidence might be a controversial one. 
It could be argued that such an attempt could confound and 
cause fright. An example was the 1995 “pill scare” when third 
generation Oral contraceptive pills were proposed to double 
venous thromboembolism risk compared with older alterna-
tives; however, this was later established not to be the case (15). 
In the interim, there was a noted increase in unintended preg-
nancies and increased rates of abortions as a result of the “pill 
scare.” This example highlights an extreme situation especially 
where new data or research have been used. For chronic condi-
tions, given the diversity and cumulative effects of numerous 
factors over a lifetime, a perfect risk assessment is unlikely to 
be delivered. In the case of epilepsy, people will still continue 
to prematurely die if steps are not put in place to reduce their 
risks. Those bereaved by the condition and those who have sup-
ported interventions are united in their determination to stop 
any unnecessarily deaths. In such situations, evidence-based 
pragmatism with a focus on improving individual wellbeing 
and safety is the way forward. Risk stratification, while not ideal 
in current day practice, could be the lowest common acceptable 
denominator to structure current evidence into small bite-size 
packages of information to improve knowledge of clinicians, 
measure and map risk, and empower individuals as part of a 
holistic approach to epilepsy risk management as highlighted 
by this small study.
It is important to note that creating such baseline scores and 
risk stratification for known risk factors is still only a first step 
in improving awareness among clinicians and people in such 
settings. Enabling them to then have risk discussions using tools 
such as the Checklist, and work together to reduce these risks 
where possible must follow to help tackle premature mortality. 
There have been other attempts to provide collective risk factors 
toward SUDEP most notably the SUDEP-7 Inventory (16). The 
SUDEP-7 Inventory similar to the Checklist has undergone 
a range of testing. Commonalities with the Checklist include 
the use of similar background literature to evidence the risk 
factors (17). The differences are in the focus of the inventory, 
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target group, and its purpose. The SUDEP-7 risk factor items 
are primarily concentrated on seizures and are correlated to 
electro-physiological variations (18). Its principal role is to 
provide a screening inventory focused on biomarkers (18). This 
is different from the ambitions of the Checklist, which looks to 
communicate person-centered risk to individuals with a view to 
empowering them to make necessary adaptations in their day-
to-day life (19). As the two tools work differently, there could 
be a case made to use them symbiotically. This concept would 
require further testing.
The manner of discussing SUDEP is not without challenges. 
These challenges are diverse and include personal, professional, 
cultural, institutional, and resource issues (20, 21). Personal 
and professional beliefs of whether it makes a difference to 
discuss are still an ongoing debate (20, 21). Cultural attitudes 
may also play a role (21). Availability of trained physicians 
itself is a concern in many parts of the world. Where there 
are services available, often there is no time or space to have 
such sensitive conversations as about SUDEP. Thus, while 
SUDEP discussion and continued risk mitigation may be a 
“step too far” in many areas, it would still be the practice to 
aspire to.
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APPeNDiX 1
the sUDeP and seizure safety checklist 
(“checklist”) and the epsMon (22, 23)  
(As Described by sUDeP Action & 
Plymouth University)
The Checklist is a free, award-winning risk assessment tool for 
clinicians, which encompasses known modifiable and non-
modifiable risk factors of SUDEP and associated concerns with 
a view to:
• Assist clinicians to open a positive discussion with people 
about epilepsy and risk assessment;
• Support a person-centered discussion of risk, focusing on 
whether known risk factors apply to a particular individual;
• Help clinicians educate people with epilepsy about their per-
sonal risk and possible lifestyle changes, which might reduce 
those risks;
• Promote the safety goal by identifying modifiable risk factors 
which may guide management;
• Create documentary evidence for clinicians on the impact of 
the treatment plan over time and demonstrate effective clinical 
governance while enhancing individual safety;
• Provide some assurance to bereaved families that every effort 
was made to reduce risk and prevent a fatality when a death 
occurs.
An example on how to administer is provided1; clinicians can 
also register for the tool, or find out more via www.sudep.org/
checklist. The Checklist is managed by SUDEP Action (Secretariat 
and PPI Leads) and Cornwall Partnership NHS Foundation Trust 
(Clinical Leads).
1 https://www.youtube.com/watch?v=Z9KHQvsapAc.
The Checklist also underpins the content of a mobile app for 
people with epilepsy, EpSMon, which has been recognized as one 
of eight innovations selected for the current NHS Innovation 
Accelerator Programme.2 The App brings lifesaving information 
to the fingertips of adults with epilepsy, enabling them to monitor 
their own seizures and well-being between medical appoint-
ments. EpSMon also shows whether risk factors have improved 
or worsened enabling people with epilepsy to seek medical 
help sooner if required. It is free to download for iPhone and 
Android devices in the UK; further information can be found at 
www.epsmon.com. EpSMon is a partnership between Cornwall 
Partnership NHS Foundation Trust, SUDEP Action, Plymouth 
University, and Royal Cornwall Hospitals Trust. The Checklist 
and EpSMon are also part of the UK Epilepsy Commissioning 
Toolkit.3
The introduction of an app delivering education and risk 
assessment is innovative in respect to current practice, but 
easily perceived as an efficient route to providing best practice. 
The app’s ability to prompt timely assessments, assess current 
understanding, track engagement, deliver bespoke education, 
and recommend clinical support could be invaluable to the care 
for epilepsy in the community. Future identified developments 
will include medication adherence tools, the development of 
manualized approaches for services to implement the Checklist 
and EpSMon app alongside each other and will look to explore 
the potential of automatic flagging of at risk individuals to health 
teams. Use of it to reduce potential harm has been strongly 
supported by a recent Cochrane review on SUDEP prevention 
(24) and a National Institute of Health Research UK Systematic 
appraisal of emerging technologies for the diagnosis, treatment, 
and management of epilepsy (25).
2 https://www.youtube.com/watch?v=e3mECsSVgHI.
3 http://www.epilepsytoolkit.org.uk/.
